Accès ouvert
2023
article
OpenAlex
Max S. Topp, Monika Długosz‐Danecka, Aleksander B. Skotnicki, Galina Salogub et autres
BACKGROUND: The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatment of these cancers, AFM11 is a tetravalent, bispecific humanised recombinant antibody …
de, pl, ru, us, il, cz
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Max S. Topp, Monika Długosz‐Danecka, Aleksander B. Skotnicki, Galina Salogub et autres
Abstract BackgroundThe prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatment of these cancers, AFM11 is a tetravalent, bispecific humanised recombinant antibody …
de, pl, ru, us, il, cz
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Nancy L. Bartlett, Alex Francisco Herrera, Eva Domingo‐Doménech, Amitkumar Mehta et autres
In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, …
us, es, de
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Cassandra Choe-Juliak, Karenza M. Alexis, Sylvia E. Schwarz, Linta Garcia et autres
TPS3148 Background: AFM13 is a tetravalent, bispecific (anti-CD30/anti-CD16A) recombinant antibody being developed for the treatment of CD30-positive T-cell malignancies and Hodgkin lymphoma. AFM13 selectively kills CD30-positive tumor cells by engaging and activating natural killer cells and macrophages. AFM13 was well tolerated at …
de, us
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Stephen Maxted Ansell, Nancy L. Bartlett, R.W. Chen, Alex Francisco Herrera et autres
Background: ME-401, a potent and selective oral PI3kδ inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell malignancies (NCT02914938).70 pts were treated as of January 2019 and we report here results in pts with FL and …
us, es, de, jo
(code pays fourni par la source)
2018
conference-abstract
OpenAlex
Galina Salogub, Jiřı́ Mayer, František Folber, Sebastian Grosicki et autres
Abstract Background AFM11 is a bispecific, tetravalent T cell-engaging antibody construct binding to CD19 on B cell origin malignant cells such as B-precursor acute lymphoblastic leukemia (B-ALL) and to CD3 on T cells. By engaging CD3-positive T cells, AFM11 elicits T cell-mediated …
ru, cz, pl, il, gb, de
(code pays fourni par la source)
2018
conference-abstract
OpenAlex
Nancy L. Bartlett, Robert W. Chen, Eva Domingo‐Doménech, Andres Forero‐Torres et autres
Abstract Background AFM13 is a bispecific, tetravalent NK cell-engaging antibody construct binding to CD30 on CD30+ tumor cells and CD16A on NK cells. By engaging CD16A-positive NK cells, AFM13 leads to NK cell-mediated killing of CD30-positive lymphoma cells (Reusch et al., 2014) …
us, es, de
(code pays fourni par la source)
2002
article
OpenAlex
Gregory A. Cope, Greg S. B. Suh, L. Aravind, Sylvia E. Schwarz et autres
COP9 signalosome (CSN) cleaves the ubiquitin-like protein Nedd8 from the Cul1 subunit of SCF ubiquitin ligases. The Jab1/MPN domain metalloenzyme (JAMM) motif in the Jab1/Csn5 subunit was found to underlie CSN's Nedd8 isopeptidase activity. JAMM is found in proteins from archaea, bacteria, …
us
(code pays fourni par la source)
Accès ouvert
1999
article
OpenAlex
Monica Gostissa, Arnd Hengstermann, Valentina Fogal, Péter Sandy et autres
it, de
(code pays fourni par la source)
1998
article
OpenAlex
Ulrike A. Nuber, Sylvia E. Schwarz, Martin Scheffner
Recognition of substrate proteins by the ubiquitin-conjugation system is a highly specific and regulated event and involves the action of ubiquitin-conjugating enzymes (E2) and ubiquitin-protein ligases (E3). However, the E2 and E3 involved in the recognition of particular substrates have been identified …
de
(code pays fourni par la source)
Accès ouvert
1998
article
OpenAlex
Sylvia E. Schwarz, José Luís Rosa, Martin Scheffner
The hect domain protein family was originally identified by sequence similarity of its members to the C-terminal region of E6-AP, an E3 ubiquitin-protein ligase. Since the C terminus of E6-AP mediates thioester complex formation with ubiquitin, a necessary intermediate step in E6-AP-dependent …
de, es
(code pays fourni par la source)
Accès ouvert
1998
article
OpenAlex
Sylvia E. Schwarz, Kai Matuschewski, Dimitris Liakopoulos, Martin Scheffner et autres
The ubiquitin-like protein SMT3 from Saccharomyces cerevisiae and SUMO-1, its mammalian homolog, can be covalently attached to other proteins posttranslationally. Conjugation of ubiquitin requires the activities of ubiquitin-activating (E1) and -conjugating (E2) enzymes and proceeds via thioester-linked enzyme-ubiquitin intermediates. Herein we show …
de
(code pays fourni par la source)